Expertise Partners
Certis
Certis is an AI-enabled precision oncology and translational science company. Our product is “Oncology Intelligence™”—highly predictive therapeutic response data derived from advanced models of cancer. We partner with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Using our proprietary artificial intelligence/machine learning platform (CertisAI™) and more clinically relevant, patient-derived tumor models, we bring certainty to lead candidate selection and help secure clear and compelling evidence of drug efficacy. Established in 2016, Certis operates a CLIA-certified laboratory in Sorrento Valley, the heart of San Diego’s life sciences industry.
Champions Oncology
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development lifecycle. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patientderived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.
GemPharmatech
GemPharmatech Co., Ltd. is a leading company in China to provide high-quality animal model resources and services for biomedical community as well as pharmaceutical companies. Based on more than 16 years’ practice in laboratory animals of the former entity, GemPharmatech has the vision and is striving to become one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners all across the world.
LIDE
LIDE is an award-winning oncology contract research organization with 12 years of delivering drug evaluation services to 200+ clients worldwide. We offer traditional preclinical CRO services like pharmacology, PK, and biomarker studies with 70+ CDX models and 2000 patient-derived xenograft (PDX) models. Our library covers 50+ cancer types and 200+ models harbor special naturally-occurred drug-resistant and/or genetic alterations. Ask us about our proprietary tools for in-vivo drug validation in 7-10 days.
XenoSTART
XenoSTART is a global nonclinical oncology contract research organisation focused on the development and utilisation of patient-derived xenograft models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organisation. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models.
Our XPDX models are clinically annotated and include patient treatment history and outcome and are characterised through genomic profiling, histologic analysis, and in vivo drug sensitivity to relevant standards of care
Program Partners
DRL
We are a clinical research organization, which provides a variety of well-characterized biomaterials for pharmaceutical companies and research organizations, including tissue samples, cell lines, and 3D models of the tumor. We offer flexible customizable solutions for clinical and preclinical studies to reduce the costs of drug discovery.
Hub Organoids
Curesponse
Hosting Partner
Element Biosciences
Element Biosciences is transforming drug discovery with AVITI24™, a next-generation platform for high-dimensional multiomics. By integrating transcriptomic, proteomic, and morphologic data at single-cell resolution, AVITI24 provides unprecedented insights into cellular function and disease. Powered by proprietary Avidite™ chemistry, it delivers exceptional data quality, cost efficiency, and scalability—empowering researchers to accelerate therapeutic discovery and development.
Learn more at elementbiosciences.com
Innovation Partner
Labcorp
Labcorp is a global leader of innovative and comprehensive laboratory services on a mission to improve health and improve lives. With more than 10,000 studies completed, 300+ human xenografts, 50+ mouse syngeneic and 400+ PDX models, we have amassed extensive experience and deep insights to inform your discovery oncology research. Our in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies, ex vivo assessments and focal radiation capabilities provide the decision-driving data you need to advance drug candidates toward the next cancer research breakthrough.
Exhibition Partners
Studylog
Studylog's Animal Study Workflow Software® is designed for biomedical animal research and provides features for the design, planning, execution, analysis, and reporting of animal studies in a standardized, highly efficient manner, while protecting data integrity. Reducing many labs’ study-related labor by half, Studylog automates and streamlines the entire animal study process, making it easier, faster and cheaper, so researchers have more time and resources to get their job done.
Reaction Biology
Reaction Biology is a global contract research organization (CRO) that provides in vitro and in vivo services to support translational research, drug discovery and development to biopharmaceutical and academic research clients. Our comprehensive portfolio spans from early discovery to clinical stage services, with specialized expertise in preclinical in vivo pharmacology and translationally relevant orthotopic and metastatic oncology models. We offer robust in vivo tumor modeling to evaluate therapeutic efficacy, PK/PD, and biomarker response in clinically relevant systems. In addition to our in vivo services, our comprehensive platform offers protein and peptide production, biochemical and biophysical assays, cell-based and co-culture effector cell assay systems, exploratory toxicology, and GMP bioanalytical testing, enabling efficient, end-to-end support for oncology and immuno-oncology research.
Daxiang Biotech
Founded in 2018, Beijing Daxiang Biotech specializes in delivering full-scenario solutions for the organoid and organ-on-a-chip sectors. We have provided services to hundreds of enterprises and research institutions across the globe. Our patented organoid-on-a-chip technology, along with supporting automated equipment, delivers high-throughput, highly biomimetic, and automated data solutions for microphysiological system (MPS) models—solutions that have earned recognition from internationally renowned pharmaceutical firms and experts.
Event Partners
InSphero
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
